Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $46.83.

A number of equities research analysts have recently commented on the stock. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Oppenheimer lifted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research note on Monday, November 11th.

Institutional Trading of Dianthus Therapeutics

Institutional investors have recently modified their holdings of the business. FMR LLC lifted its holdings in Dianthus Therapeutics by 0.8% in the fourth quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after acquiring an additional 36,133 shares during the period. Octagon Capital Advisors LP increased its holdings in shares of Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after purchasing an additional 363,500 shares in the last quarter. TCG Crossover Management LLC acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $32,735,000. Braidwell LP boosted its holdings in Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after buying an additional 712,902 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Dianthus Therapeutics by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after buying an additional 136,633 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

DNTH stock opened at $23.67 on Friday. The company has a market cap of $700.63 million, a price-to-earnings ratio of -9.47 and a beta of 1.72. The company has a fifty day moving average price of $22.89 and a 200 day moving average price of $25.49. Dianthus Therapeutics has a 12 month low of $18.34 and a 12 month high of $33.77.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.